Table 1.

Demographics and HIV disease information of APOE ε4 carriers and noncarriers.

	Carriers a (n=26)	Noncarriers b (n=73)	p-value
Age (years)	55.1 (5.9) c	56.8 (6.7)	n.s. d
Education (years)	13.62 (3.1)	14.5 (2.9)	n.s.
Sex (Female%)	26.9%	21.9%	n.s.
Race (AA%) e	76.9%	57.5%	n.s.
Current CD4 (cells/μl)	684.5 (561.0)	612.0(450.3)	n.s.
CD4 nadir (cells/μl)	152 (330)	200 (285) f	n.s.
Disease duration (years)	26.0 (9.8)	26.0 (9.3)	n.s.
GDS g	0.34 (0.29)	0.34 (0.44)	n.s.
HAND diagnosis h	26.9%	26.0%	n.s.
On stable cART i	100%	97.3%	n.s.
Undetectable VL j	84.6%	82.2%	n.s.
History of illicit drug use k	53.8%	45.2%	n.s.
Taking medications for
- Hypertension	42.3%	45.2%	n.s.
- Diabetes	19.2%	11.0%	n.s.
- Cholesterol level l	46.2%	41.1%	n.s.

Note

^aε2/ε4 (n=2), ε3/ε4 (n=21), ε4/ε4 (n=3);

^bε2/ε2 (n=4), ε2/ε3 (n=13), ε3/ε3 (n=56);

^cAge, education, disease duration, and GDS were presented as mean (standard deviation), versus current CD4 and CD4 nadir were resented as median (IQR);

^dn.s., not significant;

^eAA, African-Americans, similar results were observed in the AA subgroup (n=62) (see Table S3 and Fig. S7 to S10);

^fone noncarrier did not provide CD4 nadir (treated as a missing value);

^gGDS, global deficits score, which was calculated from the seven neurocognitive domains [26];

^hHAND, HIV-associated neurocognitive disorders, 7 carriers (6 with asymptomatic neurocognitive impairment (ANI), and 1 with mild neurocognitive disorder (MND)), and 19 noncarriers (18 with ANI, and 1 with MND) met the HAND criteria [27];

ⁱcART, combination antiretroviral therapy;

^jSubjects with undetectable plasma viral load (VL) (<20 copies/ml), including 22 carriers and 60 noncarriers (similar results were observed in this subgroup (n=82), see Table S2 and Fig. S3 to S6), and only six PWH (2 carriers, 4 noncarriers) had a VL higher than 200 copies/ml in their blood specimens.

^kSubjects who have at least one drug abuse/dependent diagnoses based on Composite International Diagnostic Interview. Note that subjects with current illicit use is not qualified to participate the current study. In additional analyses, we included the history of illicit drug use and diabetes as covariates and obtained equivalent results.

^l11 APOE ε4 carriers and 26 noncarriers are taking medications to dyslipidemia, and 1 carrier and 4 noncarriers are taking medications for the purpose of general heart health.